{"id":"W3173725877","doi":"10.1159/000513486","title":"Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study","year":2021,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Bevacizumab; Medicine; Internal medicine; Hazard ratio; Sorafenib; Hepatocellular carcinoma; Gastroenterology; Progression-free survival; Population; Phases of clinical research; Oncology; Clinical endpoint; Randomized controlled trial; Clinical trial; Confidence interval; Cancer; Chemotherapy; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002066392,0.001069669,0.001993635,0.0002978996,0.000316749,0.0005023197,0.0007344839,0.000757555,0.002016559],"category_scores_gemma":[0.001096497,0.0003582928,0.001763876,0.0004274315,0.0006872237,0.0004987398,0.0003689356,0.001385242,0.000371874],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001120335,"about_ca_system_score_gemma":0.002396779,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002487955,"about_ca_topic_score_gemma":0.006625447,"domain_scores_codex":[0.9995542,0.0002139195,0.00002942674,0.00007768752,0.00005680755,0.00006791734],"domain_scores_gemma":[0.9992017,0.0001143211,0.0002009546,0.0000815719,0.00007491536,0.0003265665],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.928539,0.0109366,0.01428023,0.0006992671,0.003644284,0.0001268874,0.0002460595,0.0007816195,0.006558606,0.0001073072,0.001634795,0.03244531],"study_design_scores_gemma":[0.7974893,0.1423397,0.05211477,0.0000473672,0.003189948,0.0001313805,0.00009895048,0.001319332,0.001221199,0.0001941451,0.00180251,0.00005130703],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971781,0.0008947848,0.0001186907,0.0002189,0.00003864475,0.0006839544,0.0003651895,0.00002069593,0.0004810745],"genre_scores_gemma":[0.9958825,0.0006178578,0.0003596602,0.0005725253,0.00008450017,0.0008875394,0.000980798,0.000007161202,0.000607497],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002487955,"threshold_uncertainty_score":0.01092821,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1069567075284236,"score_gpt":0.3480448685584838,"score_spread":0.2410881610300601,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}